How is artificial intelligence revolutionizing cancer care, and what are the key drivers shaping the artificial intelligence in oncology market?

Artificial intelligence (AI) has rapidly emerged as a transformative force in oncology, redefining how cancers are diagnosed, treated, and monitored. The global artificial intelligence in oncology market was valued at USD 2.51 Billion in 2024 and is projected to grow at a CAGR of 28.60%, reaching USD 31.05 Billion by 2034.

This remarkable growth is propelled by the increasing demand for early cancer detection, AI-driven drug discovery, and personalized treatment planning. As cancer cases continue to rise globally—surpassing 20 million new cases annually—the healthcare sector is turning to AI to improve diagnostic accuracy, treatment precision, and patient outcomes.

Market Overview

The AI in oncology market is expanding rapidly as advanced algorithms and big data analytics become integral to cancer care. AI applications are being integrated across all oncology workflows—from diagnosis and imaging to treatment selection and patient follow-up.

Healthcare systems and research institutions are increasingly leveraging AI for its ability to analyze large, complex datasets—including genomic, histopathological, and radiological data—to uncover novel insights into cancer progression and response to therapies.

Key drivers boosting market growth include:

• Rising global cancer burden and need for faster diagnosis

• Expansion of precision oncology and personalized medicine

• Growing integration of AI in imaging analysis and pathology workflows

• Advancements in machine learning (ML) and deep learning algorithms

• Increasing collaborations between AI tech firms and healthcare institutions

• Government initiatives supporting AI adoption in cancer care

Market Size and Growth

This rapid expansion reflects the growing adoption of AI in clinical oncology, particularly in early screening, personalized medicine, and precision diagnostics. AI-powered tools are now capable of identifying subtle cancer markers invisible to the human eye, enabling early interventions and better survival outcomes.

Market Segmentation

Market Breakup by Offerings

• Software: Dominates the market, offering AI-driven diagnostic and decision-support systems.

• Hardware: Includes GPUs, sensors, and diagnostic imaging devices.

• Services: Encompasses system integration, maintenance, and consulting.

Software solutions are expected to continue leading the market, thanks to their scalability, continuous learning capabilities, and integration with healthcare IT systems.

Market Breakup by Technology

• Machine Learning (ML): Key technology for predictive analytics and drug discovery.

• Natural Language Processing (NLP): Enables interpretation of unstructured clinical data and literature.

• Context-Aware Processing and Computing: Enhances decision-making through real-time data interpretation.

• Computer Vision & Imaging Analysis: Powers cancer detection in medical images.

• Others: Includes neural networks and cognitive computing.

Machine learning and computer vision are at the forefront, significantly enhancing tumor detection accuracy and treatment personalization.

Market Breakup by Application

• Drug Discovery and Development

• Diagnosis and Early Detection

• Treatment Planning and Personalization

• Patient Engagement and Remote Monitoring

• Post-Treatment Surveillance and Care

• Data Management and Analytics

• Others

Among these, diagnosis and early detection represent the largest application segment. AI-driven imaging tools analyze CT, MRI, and mammography scans to detect abnormalities earlier than conventional methods. Meanwhile, AI in drug discovery accelerates the identification of potential anti-cancer compounds, reducing costs and timelines for clinical trials.

Market Breakup by Cancer Type

• Breast Cancer

• Lung Cancer

• Colorectal Cancer

• Brain Cancer

• Leukemia

• Lymphoma

• Others

Breast and lung cancers dominate the segment, given the extensive use of AI in mammography image analysis and lung nodule detection. AI-powered solutions like iCAD’s ProFound AI and Kheiron Medical Technologies’ Mia are improving early cancer detection and workflow efficiency.

Market Breakup by End User

• Hospitals

• Oncology Clinics

• Academic and Research Institutes

• Medical Device Companies

• Others

Hospitals and oncology clinics hold the largest market share due to rising adoption of AI-enabled systems for diagnostics, treatment optimization, and patient monitoring. Academic institutions also play a key role in developing AI algorithms and validating their clinical use.

Regional Insights

North America

North America dominates the artificial intelligence in oncology market, driven by high cancer incidence, robust R&D investment, and the presence of leading companies such as Tempus AI, Inc., Paige AI Inc., and Microsoft Corporation. The U.S. market benefits from FDA-approved AI diagnostic tools and widespread adoption in hospitals.

Europe

Europe ranks second, propelled by strong healthcare infrastructure, supportive government policies, and initiatives for AI integration in cancer screening. The U.K., Germany, and France are key contributors.

Asia Pacific

Asia Pacific is projected to experience the fastest growth rate, with countries like China, Japan, and India investing heavily in healthcare AI. Rising cancer prevalence, government-backed AI innovation programs, and digital healthcare expansion are driving adoption.

Latin America

Emerging markets such as Brazil and Mexico are witnessing increasing AI adoption in oncology imaging and research collaborations with global biotech firms.

Middle East and Africa

Gradual AI integration in oncology diagnostics is underway, particularly in the UAE and Saudi Arabia, supported by national healthcare transformation initiatives.

Key Market Trends

• Integration of AI in multimodal cancer diagnosis (imaging, genomics, and pathology).

• AI-powered drug discovery platforms accelerating oncology therapeutics.

• Cloud-based AI solutions improving data access and collaboration.

• Predictive analytics for relapse and survival rate forecasting.

• AI-enhanced radiotherapy planning for optimized dose distribution.

• Expansion of partnerships between hospitals and tech companies.

Market Growth Drivers

• Rising demand for early and precise cancer diagnosis.

• Shortage of oncology specialists, boosting automation adoption.

• Increased funding for AI-based healthcare innovation.

• AI-powered imaging solutions reducing false positives and errors.

• Personalized oncology driven by genomic and clinical data integration.

Challenges

While the AI in oncology market shows immense promise, it faces certain challenges:

• Data privacy and security issues related to patient health records.

• Lack of standardized AI validation protocols across institutions.

• Integration complexities with existing healthcare IT infrastructure.

• Ethical and liability concerns over AI-based decision-making.

Despite these challenges, continuous AI model improvement and stronger data governance frameworks are likely to mitigate barriers in the coming decade.

Key Companies in the Market

Leading players in the artificial intelligence in oncology market include:

• Aidoc

• iCAD Inc.

• Microsoft Corporation

• Cancer Center.ai

• Mursla Bio

• SkinVision

• Kheiron Medical Technologies Limited

• Therapixel

• Tempus AI, Inc.

• Paige AI Inc.

These companies are focusing on developing AI-powered imaging platforms, data analytics tools, and cloud-based oncology solutions to enhance diagnostic accuracy and patient outcomes.

Future Outlook

The future of AI in oncology lies in the convergence of data-driven insights, personalized medicine, and digital health ecosystems. With precision oncology at its core, AI will continue to:

• Enable early cancer detection through multimodal data fusion.

• Accelerate novel drug discovery through predictive modeling.

• Support clinical decision-making via AI-enabled oncology dashboards.

• Transform patient monitoring through AI-powered remote tools.

By 2034, AI is expected to be a central pillar in oncology care, driving faster, smarter, and more effective cancer management worldwide.

Uncover More Reports

Genomics Market

Legal Marijuana Market

Telemedicine Market

Skincare Devices Market

About Us:

Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others.

Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector.

Media Contact:

Company Name: Claight Corporation
Contact Person: Roshan Kumar, Digital Marketing
Email: sales@expertmarketresearch.com
Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com